Cost estimation of thyroid disorders in Germany

Thyroid

Volumn 12, Issue 10, 2002, Pages 909-914

  Kahaly, George J ^a   Dietlein, Markus ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COST; ECONOMICS; GERMANY; HUMAN; REVIEW; THYROID DISEASE; ADULT; ARTICLE; COST BENEFIT ANALYSIS; FEMALE; GOITER; HEALTH INSURANCE; IODINE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MORBIDITY; PRIORITY JOURNAL;

COSTS AND COST ANALYSIS; GERMANY; HUMANS; THYROID DISEASES;

ANTITHYROID AGENT; RADIOACTIVE IODINE;

EID: 0036808920     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072502761016548     Document Type: Article

References (30)

1. WHO/UNICEF/ICCIDD 1993 Global Prevalence of Iodine Deficiency Disorders. MDIS working paper #1. Geneva, World Health Organization.
2. Delange F 1995 Correction of iodine deficiency: Benefits and possible side effects. Eur J Endocrinol 132:542-543.
3. Delange F, Benker G, Caron P, Eber O, 1997 Thyroid volume and urinary iodine in European schoolchildren: Standardization of values for assessment of iodine deficiency. Eur J Endocrinol 136:180-187.
4. Dunn JT 1997 Iodine deficiency: Consequences and prevention. Thyroid Today 20:1-9.
5. Kahaly GJ, Dienes HP, Beyer J, Hommel G 1997 Randomized, double blind, placebo-controlled trial of low dose iodide in endemic goiter. J Clin Endocrinol Metab 82:4049-4053.
6. Pfannenstiel P 1989 The costs of continuing iodine deficiency in the Federal Republic of Germany. IDD Newsletter 5:1.
7. Gutekunst R 1993 Iodine deficiency costs Germany over one billion dollars per year. IDD Newsletter 9:29-31.
8. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB 1996 Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276:1253-1258.
9. Siegel JE, Weinstein MC, Russel LB, Gold MR 1996 Recommendations for reporting cost-effectiveness analyses. JAMA 276:1339-1341.
10. Spencer RP, Kayani N, Karameddini MK 1985 Radioiodine therapy of hyperthyroidism: Socioeconomic considerations. J Nucl Med 26:663-665.
11. Dietlein M, Knapp W, Lauterbach KW, Schicha H 1999 Economic evaluation studies in nuclear medicine: The need for standardization. Eur J Nucl Med 26:663-680.
12. Danese MD, Powe NR, Sawin CT, Ladenson PW 1996 Screening for mild thyroid failure at the periodic health examination. A decision and cost-effectiveness analysis. JAMA 276:285-292.
13. Hampel R 1995 Strumaprävalenz in deutschland gröβer als bisher angenommen. Med Klin 90:324-329.
14. Dunn JT, Crutschfield HE, Gutekunst R, Dunn AD 1993 Two simple methods for measuring iodine in urine. Thyroid 3:119-123.
15. Kohlmeier L, Kroke A, Pötzsch J, Kohlmeier M, Martin K 1993 Ernährungsabhängige Krankheiten und Ihre Kosten. Nomos Verlagsgesellschaft 27, Baden-Baden.
16. Bundesministerium für Gesundheit 1997 Daten des Gesundheitswesens. Nomos Verlagsgesellschaft 91, Baden-Baden.
17. Bundesministerium für Gesundheit 1998 Jod-Monitoring 1996. Nomos Verlagsgesellschaft 110, Baden-Baden.
18. EBM 1996 Gebrührenhandbuch. Einheitlicher Bewertungsmaβtab.
19. Schwabe U, Paffrath D 1996 Arzneiverordnungsreport 96. Gustav Fisher Verlag, Stuttgart
20. Verband deutscher Rentenversicherungsträger 1996 Statistik Rehabilitation. Band 118, Frankfurt.
21. AOK Bundesverband 1996 Krankheitsartenstatistik.
22. Statistiches Bundesamt 1996 Statistiches Jahrbuch. MetzlerPoeschel Publishers, Stuttgart.
23. Hampel R 1996 Jodmangelstrumen. Prophylaxe kontra therapie - Eine volks wirtschafliche betrachtung. Z Allg Med 72:28-34.
24. Bundesverband der Pharmazeutischen Industrie e.V. 1997 Rote Liste. Editio Cantor Verlag für Medizin, Frankfurt.
25. Merck KGAA 1997 Thyroid Report. Gmi Publishers, Darmstadt
26. Thomusch O, Weber K, Sekulla C, Dralle H 1997 Cost analysis of thyroid surgery in a university hospital. Chirurg 68:989-994.
27. Dietlein M, Moka D, Dederichs B, Hunsche E, Lauterbach KW, Schicha H 1999 Cost-effectiveness analysis: Radioiodine or antithyroid drugs as first-line therapy of hyperthyroidism due to Graves' disease. Nuklearmedizin 38:7-14.
28. Dietlein M, Geckle L, Overbeck T, Moka D, Bausch V, Troche CJ, Lauterbach K, Schicha 1997 Cost-minimization analysis for the treatment of hyperthyreosis: Strumaresection compared to radioiodine treatment. Nuklearmedizin 36:150-156.
29. Dietlein M, Lauterbach KW, Schicha H 1998 Treatment of toxic nodular goitres: Comparative costing of radioiodine therapy and surgery. Exp Clin Endocrinol Diabetes 106 (Suppl 4):S66-S70.
30. Dietlein M, Troche CJ, Moka D, Bausch V, Laterbach KW, Schicha H 1998 Consequences of new patient discharge guidelines for iodine-131 therapy cost management. Nuklearmedizin 37:26-33.